SCHEMBL23065622

SCHEMBL23065622

CCOC(=O)c1cnn(C[C@@H](C)O[Si](C)(C)C(C)(C)C)c1C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.42
HPGD P15428 8/20 0.42
ALDH1A1 P00352 7/20 0.42
MAPT P10636 6/20 0.42
L3MBTL1 Q9Y468 4/20 0.42
GAA P10253 4/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
TRPC1 P48995 1/20 0.42
TRPC3 Q13507 1/20 0.42
STIM1 Q13586 1/20 0.42
ORAI1 Q96D31 1/20 0.42
STIM2 Q9P246 1/20 0.42
CYP2C19 P33261 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 2/20 0.41
LMNA P02545 2/20 0.41
NPC1 O15118 2/20 0.41
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28436894 1.00 KDM4E (0.42) KDM4EHPGDALDH1A1MAPTL3MBTL1
SCHEMBL23065877 1.00 KDM4E (0.42) KDM4EHPGDALDH1A1MAPTL3MBTL1
SCHEMBL23038879 0.86 POLB (0.41) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL23039146 0.86 POLB (0.41) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL23038876 0.86 POLB (0.41) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL2088511 0.85 KDM4E (0.47) KDM4EHPGDALDH1A1MAPTL3MBTL1
SCHEMBL23039063 0.83 KDM4E (0.46) KDM4EHPGDALDH1A1MAPTL3MBTL1
SCHEMBL20807633 0.83 KDM4E (0.46) KDM4EHPGDALDH1A1MAPTL3MBTL1
SCHEMBL23065853 0.83 KDM4E (0.46) KDM4EHPGDALDH1A1MAPTL3MBTL1
SCHEMBL23038999 0.83 KDM4E (0.30) KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4074708-A1 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-7 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION Immunic AG (DE) 2022-10-19 EP disclosed
US-11292788-B2 IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation IMMUNIC AG (DE) 2022-04-05 US disclosed
US-20210061796-A1 IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation IMMUNIC AG (DE) 2021-03-04 US disclosed
CN-111433202-A 1- (4- (isoxazol-5-yl) -1H-pyrazol-1-yl) -2-methylpropan-2-ol derivatives and related compounds as I L-17 and IFN-gamma inhibitors for the treatment of autoimmune diseases and chronic inflammation 埃慕尼克股份公司 2020-07-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210061796-A1 IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation IFNG, IL17A, IFNAR1 KDM4E 972/4885HPGD 638/4885ALDH1A1 1850/4885
US-11292788-B2 IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation IFNG, IL17A, IFNAR1 KDM4E 972/4885HPGD 638/4885ALDH1A1 1850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.